Clinical Trial Update: A Phase 1 Clinical Trial of NTQ5082 in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial of NTQ5082 in healthy volunteers to evaluate safety and pharmacokinetics, with the condition area listing complement-mediated hemolytic diseases; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complement-mediated Hemolytic Diseases

Drugs mentioned

• NTQ5082

Snippet

Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical | Conditions: Complement-mediated Hemolytic Diseases | Phase 1 | Status: NOT_YET_RECRUITING